Clinical Trial

Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female. It will also learn about the safety of drug Nemolizumab. Researchers will compare drug Nemolizumab to a placebo (a look-alike substance that contains no drug) to see if drug Nemolizumab works to treat moderate to severe atopic dermatitis. Participants will: Take drug Nemolizumab or a placebo at baseline and every 4 weeks followed, Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the disease situation.
Trial Details
NCT Number NCT07762833
Lead Sponsor Galderma R&D
Conditions Atopic Dermatitis
Enrollment 240 participants
Start Date 2026-09-28
Primary Completion 2027-09-28 (estimated)
Study Completion 2028-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-13